My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 702 / DOI: 10.3332/ecancer.2016.702

Review

The neutrophil-to-lymphocyte ratio: a narrative review

Cellular-mediated inflammatory response, lymphocytes, neutrophils, and monocytes are increasingly being recognised as having an important role in tumorigenesis and carcinogenesis. In this context, studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) can be used as an independent prognostic factor in a variety of cancers. Particularly in breast cancer, several studies have shown that a high NLR is associated with shorter survival. Because the NLR can be easily determined from the full blood count, it could potentially provide a simple and inexpensive test cancer prognosis. This review addresses the possibilities and limitations of using the NLR as a clinical tool for risk stratification helpful for individual treatment of breast cancer patients. The potential underlying phenomena and some perspectives are discussed.

Keywords: breast cancer, inflammation, neutrophil-to-lymphocyte ratio, prognosis

Loading Article Metrics ... Please wait

Related articles

Research: Circulating and tissue biomarkers in early-stage non-small cell lung cancer

Abstract | Full Article | PDF Published: 31 Jan 2017 / DOI: 10.3332/ecancer.2017.717

Policy: Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group

Abstract | Full Article | PDF | Portuguese | Spanish Published: 26 Jan 2017 / DOI: 10.3332/ecancer.2017.716

Review: Bone metastasis risk factors in breast cancer

Abstract | Full Article | PDF Published: 24 Jan 2017 / DOI: 10.3332/ecancer.2017.715

Research: Estimation of life expectancy of patients diagnosed with the most common cancers in the Valparaiso Region, Chile

Abstract | Full Article | PDF Published: 17 Jan 2017 / DOI: 10.3332/ecancer.2017.713

Research: The presence of primary circulating prostate cells is associated with upgrading and upstaging in patients eligible for active surveillance

Abstract | Full Article | PDF Published: 10 Jan 2017 / DOI: 10.3332/ecancer.2017.711



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence